72.47

1.93% 1.3399

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $72.47, with a volume of 931.40K. It is up +1.93% in the last 24 hours and up +6.06% over the past month. Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

Previous Close:

$71.13

Open:

$70.56

24h Volume:

931.40K

Relative Volume:

0.47

Market Cap:

$13.40B

Revenue:

$2.53B

Net Income/Loss:

$-240.23M

P/E Ratio:

-45.70

EPS:

-1.5857

Net Cash Flow:

$-20.46M

1W Performance:

+4.11%

1M Performance:

+6.06%

6M Performance:

+16.80%

1Y Performance:

+8.18%

1-Day Range:

$70.23

$72.83

1-Week Range:

$67.57

$72.83

52-Week Range:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1181)

Industry

Diagnostics & Research (57)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

6,600

Twitter

@exactsciences

Next Earnings Date

2024-11-05

Latest SEC Filings

EXAS's Discussions on Twitter

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Buy
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

04:09 AM

New York State Common Retirement Fund Has $20.19 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

04:09 AM

Nov 04, 2024

3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday - Yahoo Finance

Nov 04, 2024